![Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial - The Lancet ... Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial - The Lancet ...](https://www.thelancet.com/cms/asset/3096c8d0-a770-4781-8d88-86a454f521b4/gr1.jpg)
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial - The Lancet ...
![Breast Cancer Capecitabine Tablet ( Capsy ), Prescription, As Directed By Physician at Rs 1385/pack in Nagpur Breast Cancer Capecitabine Tablet ( Capsy ), Prescription, As Directed By Physician at Rs 1385/pack in Nagpur](https://5.imimg.com/data5/DB/QM/MY-7047793/capecitabine-tablet-28-capsy-29-500x500.png)
Breast Cancer Capecitabine Tablet ( Capsy ), Prescription, As Directed By Physician at Rs 1385/pack in Nagpur
![Trifluridine–tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study - The Lancet ... Trifluridine–tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study - The Lancet ...](https://www.thelancet.com/cms/attachment/5a7d473d-8928-461e-829f-96ea7bc577ce/gr1_lrg.jpg)